2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Cimzia ® in further arthritis indications Increasing patient access Juvenile rheumatoid arthritis (JRA) • Discussion ongoing with EU and U.S. regulators to finalise the study Phase 3 design Cimzia ® Juvenile RA Rheumatoid arthritis (Japan) - two Phase 3 studies completed • Monotherapy and combination with MTX • Three active arms (100 mg , 200 mg, 400 mg), every two week dosing • Time frame: 24 weeks Cimzia ® RA Japan Phase 1 Phase 2 Phase 3 Results Q3 <strong>2011</strong> Alison, living with rheumatoid arthritis 68
CDP7851 in bone loss disorders Novel therapy with strong potential Development of novel anabolic therapy • Antibody to sclerostin potentially treating bone loss disorders, incl. osteoporosis Collaborative project with Amgen Phase 2 trials ongoing • Phase 2 study in post-menopausal osteoporosis • Estimated enrolment: 400 post-menopausal women with low bone mineral density, time-frame:52 weeks CDP7851 Post-menopausal • osteoporosis • Phase II study in fracture healing Results Q2 <strong>2011</strong> • Estimated enrolment: 400 patients, time-frame: 52 weeks CDP7851 Fracture healing Phase 1 Phase 2 Results 2012 Paulette, living with osteoporosis 69
Page 1 and 2:
2010 full-year results 3 March 2011
Page 3 and 4:
UCB: to be patient-centric global b
Page 5 and 6:
203 000 patients have now been trea
Page 7 and 8:
U.S. Business Greg Duncan, Presiden
Page 9 and 10:
Cimzia ® provides a fast response
Page 11 and 12:
Cimzia ® in rheumatoid arthritis -
Page 13 and 14:
Vimpat ® U.S. When monotherapy is
Page 15 and 16:
UCB’s status as the company with
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21 and 22: Cimzia ® roll-out in Europe and Re
Page 23 and 24: Vimpat ® in epilepsy Roll-out in E
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39 and 40: Advancing the pipeline Iris Loew-Fr
Page 41 and 42: Development pipeline with significa
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54: Significant Pipeline Q2 January pip
Page 55 and 56: UCB's Sustainable Growth Roch Doliv
Page 57 and 58: UCB's sustainable future growth Cim
Page 59 and 60: Appendix 59 59
Page 61 and 62: Geographic and therapeutic breakdow
Page 63 and 64: 2010 balance sheet € million Cash
Page 65 and 66: Shareholder structure 1 Strong and
Page 67: Cimzia ® in further arthritis indi
Page 71 and 72: Vimpat ® in epilepsy Increasing pa
Page 73: Your UCB Investor Relations team An
show all

2010 full-year results 3 March 2011 - UCB

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?